The theme of International Women's Day was "inspiring change" and GSK's take on that was to profile inspiring change in the workplace, with content published on the company's website shared via a ...

GSK has shifted towards a global marketing ... While the new CEO has made some high-profile changes to the company’s management team, there have been some changes to the way the company ...

Blue Trust Inc. lifted its position in GSK plc (NYSE:GSK – Free Report) by 16.7% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 12,505 shares of the pharmaceutical ...

Geneos Wealth Management Inc. purchased a new stake in shares of GSK plc (NYSE:GSK – Free Report) during the fourth quarter, ...

GSK has reported positive interim results ... responses while maintaining a favourable safety profile. Following these ...

GSK and the University of Oxford have entered a new research partnership to launch an immuno-prevention programme.

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40. The company’s shares opened today at p1,392.50.

This breadth of mutational coverage, in addition to high selectivity which could improve tolerability, provides potential for a best-in-class profile. Luke Miels, Chief Commercial Officer ...